Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.

已完结 10 由 John 发布于 2025/9/21 21:42:58

DOI:10.1056/nejmoa2504214
作者：Ania M Jastreboff,Donna H Ryan,Harold E Bays,Peter R Ebeling,Mia G Mackowski,Nisha Philipose,Leorah Ross,Yimeng Liu,Cassandra E Burns,Siddique A Abbasi,Nicola Pannacciulli,
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1056/nejmoa2504214

New England Journal of Medicine (NEJM)

Abstract：BACKGROUND Maridebart cafraglutide (known as MariTide) is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropi

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyCombination Energetic Materials Consisting of Strained Rings Combined with High Heat of Formation Tetrazoles